Abstract: Disclosed are B5 hybridoma and a B5 monoclonal antibody to Burkholderia mallei, Burkholderia pseudomallei, or Burkholderia thailandensis and methods of use. Also disclosed are isolated binding fragments, isolated antibody fragments, isolated monoclonal antibodies, isolated chimeric antibodies, and isolated humanized antibodies having the binding fragments of the B5 monoclonal antibody. Also disclosed are assays for detecting B. mallei, B. pseudomallei, or B. thailandensis in a sample, for detecting infection by B. mallei, B. pseudomallei, or B. thailandensis, and therapeutic methods for treating infections by B. mallei, B. pseudomallei, or B. thailandensis.

Abstract: The present disclosure relates to a method to reduce virulence of Tsukamurella comprising decreasing the expression of the mycolyltransferase C (‘tmytC”) gene. Also disclosed is a pharmaceutical composition and method of prevention and treatment of infection by inhibition of tmytC.

Abstract: A bone fixation and dynamization device comprising a first member having a first end and a second end; a second member having a first end and a second end, wherein the first end of the second member is coupled to the second end of the first member body, wherein the first member is linearly moveable relative to the second member; an actuator coupled to the first member; a feedback controller coupled to the actuator; an elongate rod having an actuator end coupled to the actuator and a fixed end fixed to the second member, wherein the actuator is operable to move the rod and the second member linearly relative to the first member responsive to the feedback controller; at least one bone engagement pin extending from the first member; and at least one bone engagement pin extending from the second member.

Abstract: A pharmaceutical dosage form comprising gelatin encapsulating a pharmaceutical composition wherein said composition is at least about 6% (weight %) ethanol and lipid wherein said lipid comprises at least about 60% (weight %) and a method of protecting gelatin from deterioration is disclosed.

Abstract: A pharmacological agent-lipid solution preparation comprising a lipophilic pharmacological agent, a desalted charged lipid and an aqueous-miscible lipid solvent such that upon introduction into an aqueous medium a suspension of lipid aggregates associated with the pharmacological agent are formed, and methods of manufacture and use.